Skip to main content
Premium Trial:

Request an Annual Quote

SkylineDx, VIB Form Molecular Diagnostics Partnership

NEW YORK — SkylineDx said on Wednesday that it is collaborating with Belgian life science research institute VIB to develop novel molecular diagnostics for unmet medical needs.

According to SkylineDx, the three-year partnership will bring together VIB's single-cell analysis and biomarker discovery expertise with SkylineDx's global network of clinical centers and physicians, as well as its diagnostic development and commercialization know-how.

The alliance will focus on high-potential in vitro diagnostic opportunities for unmet medical needs for global markets, SkylineDx said. Financial and other terms of the deal were not disclosed.

Rotterdam-based SkylineDx currently markets the Merlin assay, which is designed to predict the risk of metastasis in a patient's sentinel lymph nodes, and the MMprofiler test for multiple myeloma prognosis. Both are available as CE-IVD-marked kits in Europe and as CLIA-validated laboratory-developed tests in the US. It also offers a biomarker discovery service.

In early 2020, SkylineDx began working with BioInvent International to characterize predictive immunological signatures for cancer.